Quarterly Report • Jan 4, 2011
Quarterly Report
Open in ViewerOpens in native device viewer
This document contains a selection of translated excerpts from the german version. For full information complying with the legal standards and regulations, please revert to the official «Halbjahresbericht 2010».
30 SEPTEMBER, 2010
New Value, listed at the SIX Swiss Exchange, invests directly in promising private companies in Switzerland and neighbouring countries with above-average market and growth potential. As an investment company, New Value supports innovative business models with growth capital and accompanies the companies to market success. The portfolio covers companies of different stages of development, starting with the market introduction phase up to medium-sized enterprises with stable profits.
The portfolio contains companies active in cleantech and healthcare. New Value assigns great value to ethical business concepts and good corporate governance while selecting their portfolio companies. Criteria such as meaningfulness, social responsibility and ecological sustainability are considered by New Value as decisive competitive advantages, which affect and enhance the quality of products and services offered and thus, facilitate an above average increase of value potential.
With impact investing New Value creates ethical added value – an entrepreneurial approach based on a unique combination of economical and ethical performance.
Mycosym International AG Natoil AG Silentsoft SA Solar Industries AG ZWS Zukunftsorientierte Wärme Systeme GmbH
Bogar AG Idiag AG QualiLife AG Sensimed SA Swiss Medical Solution AG
FotoDesk Group AG
| Preface 4 |
|---|
| -------------- |
Published by New Value AG Concept IRF Communications AG Design Michael Schaepe Werbung Photos Mirjam Kluka / Bronx Fotografen, gettyimages Production MDD Management Digital Data AG Printing Swissprinters AG
Careful and sustainable handling of nature and its resources is important to New Value AG. For this reason the halfyearreport 2010 has been printed on paper which comprises at least 50% recycling fibres and at least 17.5% fresh fibres from certified forestry (FSC).
It seems everyone is talking about sustainable investments these days. Indeed, the term "sustainability" is often stretched at will to fit any conceivable business model. But beware: not everything presented under the guise of sustainability is actually sustainable! Sustainability in its true form is a clear concept, a firm belief and an inner attitude. It takes years – not a quarter – to become apparent and is evidenced by concrete actions, not words.
New Value is one of the pioneers in the area of sustainable investments. Since our founding in 2000, we have consistently invested in meaningful business concepts. Today, New Value is focused on promoting companies in the cleantech and health fields.
More than ever, new ideas for solving the most pressing societal and economic challenges of our times are in high demand. These include new approaches for increasing energy efficiency and lowering the cost of guaranteeing universal access to high-quality medical care. Companies whose activities are focused in the cleantech or health sectors also benefit from having their home base in Switzerland – New Value's investment region – particularly due to the availability of specialists in these fields.
In the cleantech industry, optimism abounds. Even some notorious skeptics are finally conceding that global warming is not merely the invention of a few fundamentalists. One of the prerequisites for effectively reducing the demand for energy and environmental emissions is the fast availability of new, environmentally friendly technologies. This requires close cooperation between science, politics and the economy. Additional growth capital is also needed to help innovative companies doing research and business in the area of sustainability and renewable energies get ahead. This is where New Value comes in.
New Value invests only in real value. The business plans for all eleven companies in our portfolio are based on tangible products and services, not on the empty promise of future developments. The New Value team puts its expertise and many years of experience to use wherever it can make a real difference and provide direct support. For the investor, New Value provides the opportunity to invest directly in a well diversified business portfolio. At the same time, by investing in New Value companies, investors can help support the sustainable development of the national economy through future growth.
In the first six months of 2010/11, per a decision made in the spring of 2010, New Value shifted its concentration to the fields of cleantech and health. In August, we began strengthening our new focus by investing in medical technology firm Sensimed SA. Further changes to round out our portfolio will follow soon. In addition, we are in advanced negotiations with several promising startup companies. At the same time, we are examining exit scenarios for individual investments.
It is our express goal to further increase the net asset value of our portfolio and reduce the decline in the share price. In the coming months, we will increase the marketability of New Value shares through a stock repurchase program for up to 10% of outstanding equity.
On behalf of the Board of Directors, I thank you for your trust. New Value's portfolio companies are in good shape, their opportunities for growth intact. In close cooperation with the management and staff, we will continue to move forward with our strategy of sustainable growth. Our actions will speak for themselves.
Kind regards,
Rolf Wägli President of the Board of Directors
In the first six months of the year, most New Value portfolio companies profited from a friendlier economic environment and the recovery of their sales markets. This development is not yet directly reflected in New Value's half-year results. Operational advances by Silentsoft SA, Swiss Medical Solution AG and QualiLife AG led to upward valuations of their positions totaling CHF 0.85 million. This was offset by value adjustments of CHF 1.64 million for Mycosym International AG due to weaker than expected performance. Overall, in the first half of 2010/2011 (as of September 30, 2010), New Value recorded a loss of CHF 1.99 million (previous year: profit of CHF 10.17 million). The loss per share equals CHF 0.67.
Equity value in terms of net asset value (NAV) now totals CHF 71.4 million. NAV per share fell 1% from CHF 24.27 at the beginning of the period on March 31, 2010, to CHF 24.12. New Value's stock price at the end of the reporting period on September 30, 2010, closed at CHF 14.00, around 12% below the price at the end of March 2010.
Portfolio expanded with the addition of Sensimed SA In August 2010, New Value invested in Sensimed SA, a spinoff of the École Polytechnique Fédérale de Lausanne (EPFL) specialized in the design, development and marketing of integrated microsystems for medical devices. Its first approved product, SENSIMED Triggerfish®, is used to continuously monitor intraocular pressure. Excessive intraocular pressure is one of the main risk factors for glaucoma, also known as "green star," a disease that damages the optic nerve and, if untreated, can lead to blindness. In August 2010, New Value invested CHF 1.75 million in Sensimed capital stock, with another CHF 1.75 million planned for December. The invested funds will be used primarily to obtain market approvals in the US and Asia and for commercialization in select regions.
Operational highlights in cleantech companies: Silentsoft, Solar Industries and ZWS gain ground Silentsoft was able to keep its sales figures stable – despite a temporary slowdown in sales growth caused by rising demand from customers for lease and service solutions. In contrast to purchases of measuring and transmission equipment, these solutions offer the advantage of recurring, stable income over the entire term of the agreement. Silentsoft also moved forward in its efforts to tap the promising waste management and green building segments. The demand from property managers for energy optimization and realtime building monitoring systems is growing rapidly.
At Solar Industries AG, SI Solutions GmbH, founded in 2009 and headquartered in Puchheim near Munich (Germany), posted particularly favorable results, breaking even ahead of schedule in the middle of the year. Meanwhile, Milan, Italy-based partner firm MX Group continued its expansion efforts. The group is currently building a module production site in New Jersey (USA) where particularly high growth rates are expected in the future.
ZWS Zukunftsorientierte Wärme Systeme GmbH, in which New Value invested EUR 1.5 million in the form of a mezzanine loan at the end of March 2010, saw yet another marked increase in sales. ZWS, which offers systems for all modern building services with a focus on renewable energy solutions, more than doubled its sales during the first half of 2010. All business areas contributed to these favorable results, with disproportionate growth in the photovoltaic division.
Natoil AG was able halt the decline in sales thanks to the recovery of the markets in the important machine building and automobile supplier industry segments. Natoil worked with an international retail chain to develop a line of biological lubricant sprays for the professional retail market. The launch of the first product line at test locations is schedule for early 2011.
Mycosym continued to feel the after-effects of the economic crisis in its two primary markets, Spain and Greece. The company was forced to cope with flagging sales of both new and existing market applications, the former being subject to market launch delays. Currently, sales activities are focused on the promising vegetable and lawn (gardening, golf) segments.
Bogar AG returned to its path of growth in the first half of 2010. The company's management reorganized its central services and key account management functions and
intensified its sales and marketing activities. In June, the general meeting of shareholders elected Peter Hänsli President of the Board of Directors. Hänsli is a proven pet industry expert who will bring greater knowledge of the industry to the company's leadership.
Idiag AG maintained its sales at the previous year's level and made some initial progress in its search for strategic partners. A SpiroTiger® respiratory training study in firefighters conducted in cooperation with Dräger Safety Schweiz produced favorable results and opened up a promising new customer segment.
QualiLife continued its efforts to expand into new markets.
Upon completion of its first major project at the private Hildebrand clinic in the Swiss canton of Ticino, QualiLife was selected once again by the clinic to provide equipment for its Day Hospital.
Other newly launched projects include the Pyramide am See clinic in Zürich, the private Villa im Park clinic in Rothrist (Switzerland) and the renowned Institut Edouard Bélin in Besançon (France).
Thanks to its close cooperation with new sales partners, Swiss Medical Solution was able to increase its sales in the first half of the year. New products for small children and assisted living patients will be released soon.
| Number of shares/ |
price per | +/- vs. | Market | Portfolio | Company | |||
|---|---|---|---|---|---|---|---|---|
| Company | Title | nominal | Currency | 30/09/2010 | 31/03/2010 | value CHF 1) | share 2) | share |
| Cleantech | ||||||||
| Mycosym International | Shares | 194,337 | CHF | 8.43 | –50.0% | 1,638,252 | 3.6% | 49.1% |
| Loan | 937,007 | CHF | 100.00% | 0.0% | 937,007 | |||
| Natoil | Shares | 125,274 | CHF | 6.34 | 0.0% | 794,015 | 3.0% | 29.9% |
| Convertible loan | 205,981 | CHF | 635.88% | +0.1% | 1,309,795 | |||
| Silentsoft | Shares | 29,506 | CHF | 180.00 | +2.2% | 5,311,080 | 7.5% | 27.5% |
| Solar Industries | Shares | 1,554,100 | CHF | 5.00 | 0.0% | 7,770,500 | 10.9% | 33.1% |
| ZWS Zukunftsorientierte | ||||||||
| Wärme Systeme | Loan | 1,500,000 | EUR | 100.00% | 0.0% | 1,992,000 | 2.8% | 0.0% |
| Health | ||||||||
| Bogar | Shares | 223,500 | CHF | 3.21 | 0.0% | 718,324 | 3.4% | 31.6% |
| Convertible loan | 521,500 | CHF | 325.96% | –0.2% | 1,699,878 | |||
| Idiag | Shares | 6,928,621 | CHF | 0.64 | 0.0% | 4,434,317 | 8.9% | 41.5% |
| Convertible loan | 518,458 | CHF | 359.52% | –0.6% | 1,863,968 | |||
| QualiLife | Shares | 816,745 | CHF | 3.02 | 0.0% | 2,468,604 | 6.1% | 41.8% |
| Loan | 1,900,000 | CHF | 100.00% | 0.0% | 1,900,000 | |||
| Sensimed | Shares | 50,000 | CHF | 35.00 | 0.0% | 1,750,000 | 2.5% | 6.4% |
| Swiss Medical Solution | Shares | 311,581 | CHF | 3.20 | –36.0% | 997,059 | 11.4% | 38.9% |
| Convertible loan | 971,281 | CHF | 324.71% | –35.8% | 3,153,807 | |||
| Convertible loan | 1,218,680 | CHF | 324.71% | +175.6% | 3,957,126 | |||
| Others | ||||||||
| FotoDesk Group | Shares | 4,502,115 | CHF | 0.67 | 0.0% | 3,001,405 | 12.7% | 45.0% |
| Convertible loan | 1,300,000 | CHF | 258.17% | +0.4% | 3,356,218 | |||
| Loan | 2,660,000 | CHF | 100.00% | 0.0% | 2,660,000 | |||
| Total | 51,713,355 | 72.7% 3) |
1) Per IFRS, the market value of the convertible loan includes a valuation of the borrowed capital portion at net present value using the effective interest method and of the option portion.
2) Based on market value including liquid and financial assets
3) Market value/net assets (degree of investment)
FotoDesk Group AG entered the business printing segment with the acquisition of the online photo and business printing divisions of Liechtenstein- and Austria-based netservice.cc media AG in July 2010. By expanding its product range, FotoDesk has become one of the few companies worldwide that can offer its customers both photo and business printing products online as well as online platforms for third-party print products.
Income from investments and loans totaled CHF 3.7 million (same period last year: CHF 19.1 million), while expenses from investment and loans decreased to CHF 4.4 million versus the same period during the previous year (CHF 7.2 million). These expenses include value adjustments for Mycosym and Swiss Medical. However, the total Swiss Medical Solution stock and loan position increased by CHF 0.21 million due to the reduction in the conversion price for one of the two convertible loans. Operating expenses totaled CHF 1.5 million (same period last year: CHF 1.4 million).
Cleantech companies represented 27.8% of the overall portfolio on September 30, 2010, with health companies accounting for 32.2%. Holdings in the FotoDesk Group made up 12.7% of the portfolio. Liquid and financial assets totaling CHF 19.4 million comprised 27.3%.
In July, the general meeting of shareholders approved a stock repurchase program for up to 10% of outstanding shares. Uncommitted funds will continue to be directly invested in innovative startup companies that add economic and ethical value with new technologies, products or services. New Value seeks to contribute to the sustainable development of the national economy through entrepreneurial activities in an effort to meet the major environmental and societal challenges of the future. In the existing portfolio, New Value will provide additional capital to help fund further growth initiatives. The New Value investment team tracks the development of startup companies of interest very carefully and is currently examining various opportunities to expand the portfolio. Its goal is to make additional new investments in the second half of 2010/11.
Peter Letter CEO of EPS Value Plus AG
Stock prices CHF 14.00 (SIX Swiss Exchange) EUR 10.43 (Frankfurt)
Net Asset Value CHF 24.12 per share
Share capital CHF 32.8 Mio.
Issued shares 3 287 233 registered shares (nominal value of CHF 10 each)
Market capitalisation CHF 46 Mio.
Listing SIX Swiss Exchange since 2006 (previously at Berne eXchange until 2006)
Xetra, Open Market Frankfurt, Exchanges of Berlin, Dusseldorf, Munich and Stuttgart
Ticker-Symbols NEWN (CH), N7V (DE) Identification Valorennumber 1081986 Wertpapierkennnumber 552932 ISIN CH0010819867
Ordinary shareholders meeting July 2011 in Zurich
Investment Manager EPS Value Plus AG Zurich (www.epsvalueplus.ch)
Management fee Pro Quartal 0.5%, gemessen am NAV
Performance fee 10%, if > or = 10% growth p.a. 20%, if > or = 15% growth p.a.
that predominantly (at least 50%) make venture investments.
Business segment: Plant technology/water management Locations: Basel, Switzerland, and Seville, Spain. Number of employees as of 09/30/2010: 5.5 full-time staff Sales development 01/01-06/30/2010: –33.1% New Value holdings as of 09/30/2010: CHF 1.64 million; corresponds to a 49.1% share of equity; additional CHF 0.94 million loan New Value Board Representative: Peter Letter Website: www.mycosym.com
p Mycosym International AG is a plant technology company that develops, produces and markets innovative biological soil conditioners using mycorrhiza technology (natural symbiosis of plant roots and soil fungi). Mycosym products improve plant growth (vitalization, root volume), resulting in greater yield, higher stress tolerance and fewer losses in intensive farming, and allowing growth in extreme locations (aridity, salinity). Another benefit is substantially reduced water consumption in agriculture and gardening. In some applications, resistance to pests and illnesses is increased.
p New Value increased the existing loan in the reporting period by CHF 0.28 million, with the additional funds provided proportionally by institutional co-investors and management.
p The value of the stock position was adjusted due to the substantial sales shortfall to CHF 8.43 per share (at March 31, 2010: CHF 16.86) for a new total valuation of CHF 1.64 million. The CHF 1.64 million devaluation was based on new corporate projections and calculated using the discounted cash flow method. The loan for CHF 0.94 million was recognized at face value with no change. The Mycosym position as a whole was devalued by CHF 1.64 to CHF 2.58 million.
Business segments: energy-efficient lubricants made using renewable raw materials Location: Immensee (Schwyz), Switzerland Number of employees as of 09/30/2010: 2.0 full-time staff Sales development 01/01-06/30/2010: –20.7% New Value holdings as of 09/30/2010: CHF 0.79 million; corresponds to a 29.9% share of equity; additional CHF 1.31 million convertible loan New Value Board Representative: Peter Letter Website: www.natoil.ch
p Natoil AG develops and distributes industrial lubricants with first-rate technical qualities made as much as possible using renewable raw materials. Thanks to lower friction losses, their use allows substantial energy savings, less wear and tear and further performance improvements, such as the shortening of cycle times in injection molding machines and presses. The demand for energyefficient and environmentally friendly solutions and the long-term trend toward higher prices for mineral oil products underscore the market potential for Natoil lubricants. Natoil uses seeds from a special type of sunflower cultivated in Europe as its primary raw ingredient. This variation of the sunflower does not compete with food production.
cooperating with partners who are already active in these segments, Natoil will be able to enter the market more quickly.
p Valuation at CHF 6.34 per share took place using the discounted cash flow method and took into account the dilution effect of outstanding convertible loans (at March 31, 2010: CHF 6.34). The value of the stock position thus remained unchanged at CHF 0.79 million. The market value of the convertible loan includes a valuation of the borrowed capital portion at net present value using the effective interest method and of the option portion. Compared to March 31, 2010, the value of the loan remained unchanged at CHF 1.31 million. The total value of the Natoil position thus remained unchanged at CHF 2.10 million.
Business segments: Information technology/M2M telemetry with a strong focus on cleantech applications Location: Morges (Vaud), Switzerland Number of employees as of 09/30/2010: 27 full-time staff Sales development 01/01- 06/30/2010: +0% New Value holdings as of 09/30/2010: CHF 5.31 million; corresponds to 27.5% share of equity New Value Board Representative: Dr. Marius Fuchs (New Value cooperation partner) Website: www.silentsoft.com
p Silentsoft SA is a leading provider of machine to machine (M2M) communication technology with a strong focus on the cleantech sector. Silentsoft's proprietary technology features processes and software that make it possible to operate large M2M remote monitoring networks for measuring, automatically transmitting and analyzing data from geographically distributed containers for liquids, powders or waste products. Silentsoft has become Europe's leading provider of wireless M2M network services for building management and now offers additional solutions for waste management and recycling. Over 30,000 systems in 12 European countries provide customers with the necessary real-time data for reducing their energy and transportation costs and CO2 emissions.
and real-time building monitoring are increasingly in demand from property managers.
p Valuation of the stock position at CHF 180.00 per share (at March 31, 2010: CHF 176.13) corresponds to the price at the capital increase conducted in September 2010 and led to another upward valuation of the overall position by CHF 0.02 million to CHF 5.31 million.
Business segments: Solar industry firms along the value chain for PV solar module manufacturing and marketing Locations: Niederurnen (Glarus), Switzerland; Milan, Italy; and Puchheim, Germany Number of employees as of 09/30/2010: 15 full-time positions and external partners (including non-fully-consolidated companies: 242 full-time staff) Sales development: TBD New Value holdings as of 09/30/2010: CHF 7.77 million; corresponds to 33.1% share of equity New Value Board Representative: Rolf Wägli (President) Website: www.solarindustries.ch
p Solar Industries AG follows a growth and buy-and-build strategy with new and existing companies along the value chain of solar module manufacturing and marketing. Solar Industries strives toward a competitive industrial integration of these companies. Its subsidiary SI Solutions GmbH of Puchheim near Munich (majority interest) is a distribution company and system integrator. It offers photovoltaic systems to installers and project developers. In Italy, Solar Industries works with Milan-based MX Group SpA (minority interest). The MX group operates production sites for photovoltaic solar modules. It also plans and realizes solar parks. In addition, the MX Group invests in the expansion of production facilities for solar cells and solar modules. Investments in the important solar markets of Italy and Germany will serve as a platform for expansion into other European and overseas markets.
currently building a module production site in New Jersey (USA) with a partner firm. High growth rates are expected in the US solar market in the next several years.
p Valuation at CHF 5.00 per share corresponds to the price at the last capital increase in December 2008 (at March 31, 2010: CHF 5.00) and resulted in an unchanged valuation of the stock position at CHF 7.77 Mio.
Business segments: System provider of renewable-energy-based solutions for modern building services such as heating, photovoltaic or rainwater harvesting systems Locations: Neukirchen-Vluyn, Germany (headquarters) and 13 other locations in Germany and Austria Number of employees as of 09/30/2010: 60 full-time staff Sales development 01/01- 06/30/2010: +156.8% New Value holdings as of 09/30/2010: EUR 1.5 Mio. mezzanine loan New Value Board Representative: none Website: www.zws.de
p ZWS offers innovative and future-oriented heat and energy systems. Products include systems for all modern building services with a focus on renewable energybased solutions: thermal solar systems (hot water, heating system support), photovoltaic systems, heating (heat pumps, pellet, wood, storage solutions), system technology (building systems combining different technologies), ventilation (heat recovery and cooling) and sanitary and rainwater recycling. As a system provider, ZWS outsources the manufacture of its products and sells them under the ZWS brand or, in some cases, under third party manufacturer brands. ZWS develops its own innovative solutions in cooperation with manufacturers. ZWS places great emphasis on replicable sales structures and serves primarily direct customers (new construction and renovation) with its high degree of consulting expertise. ZWS has therefore developed modular product concepts. Since its founding in the late 1990s, the business has been gradually expanded and now comprises 14 locations throughout Germany and Austria.
such as wood can also be easily integrated – SANUSOL 600 already offers the necessary variety of connection options.
p New Value invested EUR 1.5 million in ZWS in the first quarter of 2010 in the form of a mezzanine loan. The fast growth of ZWS, with an over 40% sales increase in the last three years, required additional growth capital, which was provided by New Value during this financing round.
p The mezzanine loan was recognized at its nominal value of EUR 1.50 million (CHF 1.99 million). New Value conducted a forward currency deal to hedge against foreign currency risk in its EUR loan to ZWS.
Business segments: Animal health and nutrition using plant-based ingredients Location: Wallisellen, Switzerland Number of employees as of 09/30/2010: 8 full-time staff Sales development 01/01-06/30/2010: +16.6% New Value holdings as of 09/30/2010: CHF 0.72 million; corresponds to 31.6% share of equity; additional CHF 1.70 million convertible loan New Value Board Representative: Rolf Wägli Website: www.bogar.com
p Bogar AG is a specialist in natural and future-oriented pet health and nutrition that develops, produces and distributes high-quality herbal pet food supplements and care products. Bogar is a pioneer in the field of veterinary phytotherapy. The continuously expanding product line consists of effective nutritional supplements as well as high-quality care compounds for dogs, cats and sporting and recreational horses.
p In March 2010, Bogar raised CHF 1.3 million in new financing. New Value invested CHF 0.75 in the form of equity capital and convertible loans. Additional investments were made by new and existing investors as well as management. The funds will be used to expand the product range and distribution network.
p Valuation at CHF 3.21 per share took place using the discounted cash flow method and took into account the dilution effect of outstanding convertible loans (at March 31, 2010: CHF 3.21). The value of the stock position thus remained unchanged at CHF 0.72 million. The market value of the convertible loan includes a valuation of the borrowed capital portion at net present value using the effective interest method and of the option portion. Compared to March 31, 2010, the value of the loan remained unchanged at CHF 1.70 million. The total value of the Bogar position thus remained unchanged at CHF 2.42 million.
Idiag AG
Business segments: Back and respiratory diagnostics and rehabilitation Locations: Fehraltorf (Zürich), Switzerland, and Bad Säckingen, Germany Number of employees as of 09/30/2010: 10 full-time staff Sales development 01/01-06/30/2010: –1% New Value holdings as of 09/30/2010: CHF 4.43 million; corresponds to 41.5% share of equity; additional CHF 1.86 million convertible loan New Value Board Representative: Paul Santner (President) Website: www.idiag.ch
p Idiag AG develops and distributes innovative products for medicine and sports applications in the back care and respiration growth segments. MediMouse® is a convenient measuring system for computer-assisted imaging and radiation-free examination of the shape and mobility of the spinal column for diagnostics and therapy assistance. SpiroTiger® Medical is a respiratory training device used to improve the performance and endurance of respiratory muscles for medical treatment (for example, shortness of breath in COPD patients, snoring, sleep apnea and cystic fibrosis). Idiag markets SpiroTiger® Sport to the sports market for endurance and strength training of the respiratory muscles.
able method for treating shortness of breath and weak conditioning in these patient groups.
p Valuation at CHF 0.64 per share took place using the discounted cash flow method and took into account the dilution effect of outstanding convertible loans (at March 31, 2010: CHF 0.64). This corresponds to the price paid by a new shareholder for a new capital contribution in late 2009. The value of the stock position thus remained unchanged at CHF 4.43 million. The market value of the convertible loan includes a valuation of the borrowed capital portion at net present value using the effective interest method and of the option portion. This resulted in a slightly lower value of CHF 1.86 million (at March 31, 2010: CHF 1.88 million). Overall, there was a slight reduction in the total Idiag position of CHF 0.01 million to CHF 6.30 million.
Business segments: Patient communications platform for the health industry Locations: Opfikon and Lugano, Switzerland Number of employees as of 09/30/2010: 7 full-time staff Sales development: In the market launch stage; first major project completed New Value holdings as of 09/30/2010: CHF 2.47 million; corresponds to 41.8% share of equity; additional CHF 1.9 million loan New Value Board Representative: Thomas Keller Website: www.qualilife.com
p QualiLife AG is a software company that specializes in developing multimedia and entertainment solutions for hospital patients. QualiLife's newest development, QualiMedical UCS (Unified Communication Solution), is an innovative software platform that allows patients in hospitals and rehab clinics to access TV, radio, telephone and the internet or to watch videos. Through interfaces to the administration systems and software applications, bedside activity recording and targeted patient information, the solution supports work processes in the clinic, thus helping improve efficiency and quality. In addition to applications for clinics, QualiLife offers additional solutions for persons with disabilities and the elderly.
p QualiLife received the Health Media Award for its "QualiMedical Unified Communication Solution" from Trendforum Gesundheit of Cologne, Germany. Swisscom, along with Cisco and Microsoft, presented examples of ICT solutions in practice at the "Swiss Dialogue Arena" event in September 2010, including the QualiLife solution at Clinica Hildebrand in Brissago (Switzerland). QualiLife made additional appearances at the eSummit in Bern, the Hospital Director Day in Zurich and the eHealthCare.ch conference in Nottwil.
p At the start of September 2010, QualiLife acquired new office spaces, including a representative show room in Zürich-Opfikon.
p Valuation at CHF 3.02 per share took place using the discounted cash flow method (at March 31, 2010: CHF 3.02). Third-party loan conversions at higher share prices were not used as price indicators as a precautionary measure. Shares received as part of a stock transfer led to a value adjustment of CHF 0.47 million. The value of the stock position thus increased to CHF 2.47 million. The loan for CHF 1.9 million was recognized at face value. The total position, including the total upvaluation of CHF 0.47 million, now amounts to CHF 4.37 million.
Business segments: Diagnostics Location: Lausanne (Vaud), Switzerland Number of employees as of 09/30/2010: 14 full-time staff Sales development: in market launch phase New Value holdings as of 09/30/2010: CHF 1.75 million; corresponds to 5.8% share of equity New Value Board Representative: Sonja Keppler (Gastrecht) Website: www.sensimed.ch
p Sensimed was founded in 2003 as a spinoff of EPFL and is specialized in the design, development and marketing of integrated microsystems for medical devices. Its first approved product, SENSIMED Triggerfish®, is used to continuously monitor intraocular pressure. Excessive intraocular pressure is one of the main risk factors for glaucoma (green star). Glaucoma is a slowly progressive, irreversible disease that can damage the optic nerve and, if untreated, can lead to blindness. Early and adequate treatment is therefore critical for patients. The solution developed by Sensimed allows the continuous measurement of intraocular pressure 24 hours a day and is the first to deliver information regarding pressure fluctuations during the night. The company's management and board of directors bring many years of experience in the field of medical technology. SENSIMED Triggerfish® has earned the support of opinion leaders in the field of glaucoma research. Various clinical studies have proven the safety and tolerability of the solution. Sensimed has received numerous accolades, including the 2010 R&D 100 Award, the CTI Medtech Award, the Red Herring 100 Europe Award and the DeVigier Foundation Award.
ment of established milestones. The invested funds will be used to obtain market approvals in the US and Asia, to market the solution in select regions, to conduct post-marketing studies and to finance ongoing business operations. Another important project involves the funding of studies of SENSIMED Triggerfish® by health insurance providers in select countries.
Value Drivers
p Valuation at CHF 35.00 per share corresponds to the acquisition price at the capital increase held in August 2010 and resulted in a valuation of the stock position at CHF 1.75 million.
Business segment: In-vitro diagnostics for self-tests Location: Büron, Switzerland Number of employees as of 09/30/2010: 8 full-time staff Sales development 01/01-06/30/2010: +53.9%. New Value holdings as of 09/30/2010: CHF 1.0 million, corresponds to a 38.9% share of equity; additional CHF 7.11 million convertible loan New Value Board Representative: Peter Letter Website: www.swissmedicalsolution.ch
p Swiss Medial Solution AG developed a unique, patented platform technology for in-vitro diagnostics designed especially for home testing. The company has begun by producing and selling custom-tailored self-tests for early indication of urinary tract infections in women with recurring urinary tract infections (U-Lab®). Other products for small children and assisted living patients will be launched soon.
p Valuation at CHF 3.20 per share took place using the discounted cash flow method and took into account the dilution effect of outstanding convertible loans (at March 31, 2010: CHF 5.00). The value of the stock position was adjusted by CHF -0.56 million to CHF 1.0 million primarily due to the dilution effect of the lower conversion price. The market value of the convertible loan includes a valuation of the borrowed capital portion at net present value using the effective interest method and of the option portion. Due to attractive conversion terms, the convertible loan was recognized at CHF 7.11 million, representing an upward valuation of CHF 0.77 million based primarily on the value of the option portion as per IFRS guidelines (at March 31, 2010: CHF 6.34 million). The value of the Idiag position as a whole increased by CHF 0.21 to CHF 8.11 million.
Business segments: E-commerce company in the online photo service and business printing segments Locations: Zug and Basel, Switzerland, Liechtenstein and India Number of employees as of 09/30/2010: 52 full-time staff Sales development 01/01- 06/30/2010: -20% (excluding acquisition) New Value holdings as of 09/30/2010: CHF 3.0 million, corresponds to a 45% share of equity; additional CHF 3.35 million convertible loan and CHF 2.66 million loan New Value Board Representative: Peter Letter (President) Website: www.fotodesk.com
p FotoDesk Group AG is an integrated company in the digital imaging services and business printing segment offering not only high-quality photo books but also innovative lifestyle products such as posters or images on glass and canvas. FotoDesk expanded its offerings with an online boutique for fine art prints. Through its merger with online portal www.flauntr.com, customers can also access high-quality image editing applications. These are gradually being integrated into FotoDesk's online services. With the expansion of its product range in July 2010 to include business printing, FotoDesk is now one of the few companies worldwide that can offer its customers both photo and business printing products online as well as online platforms for third-party print products. The company provides digital imaging services via its websites www.colormailer.com, www.fastlab.com and www.netfoto.cc, and brochures, posters, stationery and business cards at www.netprint.cc.
p New Value increased its existing loan in the reporting period in multiple stages by CHF 2.41 million. The new funds were used by FotoDesk primarily to finance the acquisition.
p Valuation at CHF 0.67 per share took place using the discounted cash flow method and took into account the dilution effect of outstanding convertible loans (at March 31, 2010: CHF 0.67). The value of the stock position thus remained unchanged at CHF 3.0 million. The market value of the convertible loan includes a valuation of the borrowed capital portion at net present value using the effective interest method and of the option portion. This resulted in a slightly higher value of CHF 3.35 million (at March 31, 2010: CHF 3.34 million). The loan for CHF 2.46 million was recognized at face value. There was therefore a slight increase in the total value of the FotoDesk position, which now equals CHF 9.02 million.
(UNAUDITED)
| 9/30/10 | 3/31/10 | ||
|---|---|---|---|
| Item | Note | CHF | CHF |
| Non-Current Assets | ||
|---|---|---|
| Venture Capital Investments 5.2. |
28,883,556 | 27,130,519 |
| Long-term Convertibles and Loans 4.2/4.3. |
19,677,799 | 17,226,105 |
| Total Non-Current Assets | 48,561,355 | 44,356,624 |
| Current Assets | ||
| Short-term Convertibles and Loans 4.1. |
3,152,000 | 2,395,150 |
| Other accounts receivable | 37,755 | 34,902 |
| Accruals | 786,472 | 203,941 |
| Cash and cash equivalents | 19,432,309 | 31,129,585 |
| Total Current Assets | 23,408,536 | 33,763,578 |
| Total Assets | 71,969,891 | 78,120,202 |
| Shareholders Equity | ||
|---|---|---|
| Share capital paid-in 6 |
32,872,330 | 32,872,330 |
| Treasury Shares 6.4. |
–4,551,701 | –1,594,404 |
| Share premium | 19,464,904 | 20,411,492 |
| Accumulated profit/loss carried forward | 23,609,220 | 25,603,325 |
| Total Shareholders' Equity | 71,394,753 | 77,292,743 |
| Liabilities | ||
| Deferrals | 575,138 | 827,459 |
| Total Liabilities | 575,138 | 827,459 |
| Total Liabilities and Shareholders' Equity | 71,969,891 | 78,120,202 |
(UNAUDITED)
| 04/01/2010 – 09/30/2010 |
04/01/2009 – 09/30/2009 |
||
|---|---|---|---|
| Item | Note | CHF | CHF |
| Income from investments and loans | |||
| Income from sale of investments | 5.2. | 0 | 553,336 |
| Unrealised income from investments, loans and convertibles | 4/5.2. | 3,325,309 | 18,426,091 |
| Interest income | 418,913 | 88,824 | |
| Total income from investments and loans | 3,744,222 | 19,068,251 | |
| Expenses from investments and loans | |||
| Unrealised losses from investments, loans and convertibles | 4/5.2. | –4,270,527 | –7,238,383 |
| Investment expenses | –5,849 | –8,070 | |
| Total expenses from investments and loans | –4,276,376 | –7,246,453 | |
| Operating expenses | |||
| Investment management fee | 8 | –766,371 | –703,110 |
| External personnel expenses | –48,420 | –48,420 | |
| Expenses Board of Directors | –207,400 | –228,917 | |
| Expenses auditors | –49,363 | –46,875 | |
| Expenses Communication/Investor Relations | –254,836 | –261,292 | |
| Consulting costs (Legal and Tax) | –36,586 | –214 | |
| Other administrative expenses | –93,524 | –77,789 | |
| Tax | –50,000 | –60,000 | |
| Total operating expenses | –1,506,499 | –1,426,617 | |
| Financial income and expenses | |||
| Financial income | 204,046 | 27,098 | |
| Financial expenses | –159,497 | –251,621 | |
| Total financial income and expenses | 44,549 | –224,523 | |
| Earnings before taxes | –1,994,105 | 10,170,658 | |
| Income tax | 0 | 0 | |
| Halfyear loss/profit | –1,994,105 | 10,170,658 | |
| Other profit or loss | 0 | 0 | |
| Overall result | –1,994,105 | 10,170,658 | |
| Average number of shares outstanding | 2,980,974 | 2,996,574 | |
| Result per share undiluted | 9 | -0.67 | 3.39 |
| Result per share diluted | 9 | -0.67 | 3.39 |
New Value AG Bodmerstrasse 9 Postfach CH-8027 Zürich Telefon +41 43 344 38 38 Fax +41 43 344 38 39 [email protected] www.newvalue.ch
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.